Citius Oncology, Inc. (CTOR)
0.80
+0.01
(+0.98%)
USD |
NASDAQ |
Sep 04, 13:57
Citius Oncology Debt to Equity Ratio : 0.2528 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.2528 |
| March 31, 2026 | 0.1077 |
| December 31, 2025 | 0.0651 |
| September 30, 2025 | 0.0847 |
| June 30, 2025 | 0.1173 |
| March 31, 2025 | 0.1066 |
| December 31, 2024 | 0.092 |
| September 30, 2024 | |
| June 30, 2024 | 0.0373 |
| March 31, 2024 | 0.0331 |
| December 31, 2023 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| January 31, 2022 | |
| October 31, 2021 | |
| July 31, 2021 | |
| April 30, 2021 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Citius Pharmaceuticals, Inc. | 0.1077 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 112.09M |
| Total Liabilities (Quarterly) | 71.71M |
| Shareholders Equity (Quarterly) | 40.38M |
| Current Ratio | 0.7265 |
| Net Debt Paydown Yield | -1.86% |